An international research team led by Anshuman Dasgupta and Professor Twan Lammers from the Institute for Experimental Molecular Imaging at RWTH Aachen University succeeded in generating stable non-spherical microbubbles. In collaboration with Profes
CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea
News provided by
Share this article
Share this article
SAN CARLOS, Calif., May 11, 2021 /PRNewswire/ CAGE Bio Inc., a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced dosing of the first patient in its Phase 2 clinical trial for the treatment of inflammatory lesions of rosacea.
The 12-week randomized double-blind vehicle-controlled trial is testing CAGE Bio s novel ionic-liquid based product CGB-400 Topical Gel. Patients diagnosed with moderate to severe rosacea with inflammatory lesions on their face will be enrolled in the study at four sites in the US and randomized to an active or vehicle arm.
Share this article
Share this article
BOSTON, April 6, 2021 /PRNewswire/ Droplette, a clinically-validated breakthrough skincare delivery system that transforms dermatologist-recommended skincare ingredient serums into a powerful micro-mist, has officially launched. A recent NewBeauty 2021 award winner for the Innovations category, Droplette, allows for the effective delivery of skincare deep into the skin, delivering molecules that are 10,000x larger than what could traditionally be absorbed by your skin topically, achieving this feat without needles or pain. This patented technology can effectively help achieve results at home that were previously only possible through treatments with a dermatologist.
Droplette
Droplette can cross the skin barrier that most topical skincare creams and serums can t. In fact, 90% of skincare ingredients applied topically never absorb beyond the surface of your skin. The skin s outer layer does a remarkable job at protecting the body again
Share this article
Share this article
SAN CARLOS, Calif., Feb. 16, 2021 /PRNewswire/ CAGE Bio Inc., an innovative biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced the closing of a $7.2 million over-subscribed Series A financing. The investment was led by professional and angel investor groups consisting of current and former pharmaceutical executives and physicians.
CAGE Bio s mission is to translate ionic liquids into transformational consumer healthcare and prescription therapeutics. The financing will enable CAGE Bio to strengthen the team, launch consumer healthcare products, and advance their lead therapeutic product for papulopustular rosacea to phase 2. The support of investors with proven track records in the healthcare space is validation of the therapeutic benefits and disruptive potential of ionic liquids, said Nitin Joshi, co-founder and chief executive officer, CAGE Bio. We are exc